• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Assessment of Knowledge Regarding Risks and Benefits of the Use of Non-Vitamin K Antagonist Oral Anticoagulants
CONCLUSIONS: There is an opportunity to improve NOAC-related knowledge in patients with atrial fibrillation. When developing educational interventions, patient characteristics associated with poor knowledge should be considered. Based on our results, these are patients who are older, more medically complex, are on apixaban, and have been on NOAC therapy for a shorter duration.PMID:36000450 | DOI:10.1177/21501319221118806
Source: Primary Care - August 24, 2022 Category: Primary Care Authors: Jose Raul Valery Ahmad Marar George Pujalte Cynthia Ward Yousif M Abdelmoneim Patrick J Fitzgerald Edson Mwakyanjala Dana M Harris Loren Murray Michael G Heckman Launia J White Fernando Stancampiano Source Type: research

Anticoagulation: Updated Guidelines for Outpatient Management.
Abstract Anticoagulation therapy is recommended for preventing, treating, and reducing the recurrence of venous thromboembolism, and preventing stroke in persons with atrial fibrillation. Direct oral anticoagulants are first-line agents for eligible patients for treating venous thromboembolism and preventing stroke in those with nonvalvular atrial fibrillation. Vitamin K antagonists are recommended for patients with mechanical valves and valvular atrial fibrillation. Vitamin K antagonists inhibit the production of vitamin K-related factors and require a minimum of five days overlap with parenteral anticoagulants, ...
Source: American Family Physician - September 30, 2019 Category: Primary Care Authors: Wigle P, Hein B, Bernheisel CR Tags: Am Fam Physician Source Type: research

Effectiveness, safety and costs of stroke prevention in non-valvular auricular fibrillation. Study of cohorts matched by Propensity score.
CONCLUSIONS: Most patients initiated VKA. We found no differences between VKA and dabigatran in the risk of stroke, haemorrhages or mortality. PMID: 31551166 [PubMed - as supplied by publisher]
Source: Atencion Primaria - September 20, 2019 Category: Primary Care Authors: Giner-Soriano M, Casajuana M, Roso-Llorach A, Vedia C, Morros R Tags: Aten Primaria Source Type: research

Thromboembolic and haemorrhagic events in patients with atrial fibrillation: a prospective cohort study in UK primary and secondary care.
CONCLUSION: Anticoagulants are associated with lower risk of thromboembolic and haemorrhagic events among patients with AF than antiplatelets. More research is required on the risk associated with VKAs or NOACs. PMID: 31015222 [PubMed - as supplied by publisher]
Source: The British Journal of General Practice - April 22, 2019 Category: Primary Care Authors: Robson J, Mathur R, Priebe M, Ahmed Z, Ayerbe L Tags: Br J Gen Pract Source Type: research

Variation in anticoagulation for atrial fibrillation between English clinical commissioning groups: an observational study.
CONCLUSION: Anticoagulation for AF has improved substantially in England in association with considerable increases in the eligible population as a result of decreased exception reporting and the use of the CHA2DS2VASc score. There is still substantial room for improvement in most CCGs because, even allowing for exceptions, nine out of 10 CCGs failed to achieve 90% anticoagulation. PMID: 29970397 [PubMed - as supplied by publisher]
Source: The British Journal of General Practice - July 2, 2018 Category: Primary Care Authors: Robson J, Homer K, Ahmed Z, Antoniou S Tags: Br J Gen Pract Source Type: research